Get started
Author

Sascha Tillmanns

Observed name: S. Tillmanns
Institution: BioNTech (Germany)
OpenAlex ID: A5046261996
Lung Deposition of a Liposomal Cyclosporine A Inhalation Solution in Patients after Lung Transplantation
2009 · Juergen Behr, Gregor Zimmermann, et al. · Journal of Aerosol Medicine and Pulmonary Drug Delivery · 74
A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis
2019 · Wojciech Jurczak, Pier Luigi Zinzani, et al. · Blood · 25
Interim Results From a Phase Ib/IIa Clinical Trial with the Soluble Fc-Gamma IIb Receptor SM101 for the Treatment of Primary Immune Thrombocytopenia
2012 · Tatyana Semenovna Konstaninova, Ivanova Valentina Leonidovna, et al. · Blood · 19
Comparative permeability and diffusion kinetics of cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood ex vivo
2008 · Beatrice Trammer, Annette Amann, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 15
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
2022 · Elena Garralda, Aung Naing, et al. · Journal of Clinical Oncology · 13
RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
2020 · Grzegorz S. Nowakowski, Thomas David Rodgers, et al. · Journal of Clinical Oncology · 12
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
2025 · Stephane Champiat, Elena Garralda, et al. · Cell Reports Medicine · 6
DB-1305/BNT325, a novel trophoblast cell-surface antigen 2 antibody-drug conjugate, in patients with ovarian cancer: Efficacy and safety data from a phase I/II study
2025 · Maria Rubinstein, Bhavana Pothuri, et al. · Gynecologic Oncology · 4
Abstract 648: Activity of BNT327/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325/DB-1305 (TROP2 ADC) in solid tumors: Early preclinical and clinical evidence to support BNT327 + ADC combinations
2025 · Erika P. Hamilton, Jianqing Zhu, et al. · Cancer Research · 4
ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
2021 · Umberto Vitolo, Grzegorz S. Nowakowski, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
REDUCED NEAR‐UV SENSITIVITY IN Phycomyces MUTANTS AFFECTED IN THE BIOSYNTHESIS OF 6,7‐DIMETHYL‐8‐RIBITYLLUMAZINE
1995 · Sascha Tillmanns, Horst Senger, et al. · Photochemistry and Photobiology · 4
Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial
2022 · Stephane Champiat, Aurelien Marabelle, et al. · Cancer Research · 3
716 AURELIO-04: a phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors
2022 · Stephane Champiat, Aurelien Marabelle, et al. · Regular and Young Investigator Award Abstracts · 2
PDF
ABCL-135: RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2020 · Thomas Rodgers, Pier Luigi Zinzani, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Abstract PS5-02-29: Clinical data of DB-1305/BNT325 (TROP2 antibody-drug conjugate [ADC]) in patients (pts) with metastatic triple negative breast cancer (mTNBC): Efficacy and safety data from a phase 1/2 trial
2026 · E. Hamilton, D. A. Aysel, et al. · Clinical Cancer Research
557P First clinical data of DB-1305/BNT325 (TROP2 antibody-drug conjugate [ADC]) in patients (pts) with pretreated triple-negative breast cancer (TNBC): Efficacy and safety data from a phase I/II trial
2025 · E. Hamilton, M. Yan, et al. · Annals of Oncology
Supplementary Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
2023 · Pier Luigi Zinzani, Thomas Rodgers, et al.
Supplementary Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
2023 · Pier Luigi Zinzani, Thomas Rodgers, et al.
Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
2023 · Pier Luigi Zinzani, Thomas Rodgers, et al.
Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
2023 · Pier Luigi Zinzani, Thomas Rodgers, et al.
Poster: ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
2021 · Umberto Vitolo, Grzegorz S. Nowakowski, et al. · Clinical Lymphoma Myeloma & Leukemia
O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND)
2021 · Grzegorz Nowakowski, Thomas Rodgers, et al. · Annals of Oncology
PDF
A phase Ib/IIa clinical trial to investigate the safety and efficacy of recombinant human soluble Fc-gamma receptor IIb (SM101) for intravenous application in the treatment of patients with chronic adult idiopathic thrombocytopenic purpura (ITP)
2013 · Sascha Tillmanns
SM101 In systemic Lupus Erythematosus patients with or without a history of lupus nephritis
2012 · Sascha Tillmanns
Works count: 24
Citation count: 187
H-index: 6
I10-index: 6
Year
Topic
Type